Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
standard-of-care + dexmedetomidine
- Development stage
- Phase 3
- Lead developer
- BioXcel Therapeutics
- Modality
- Small Molecules
- Administration
- Intravenous, Sublingual
01
Overview
This combination approach involves adding dexmedetomidine to standard-of-care sedation protocols. Dexmedetomidine is an alpha-2 adrenoceptor agonist that provides sedation without significant respiratory depression. When added to standard sedation protocols (which may include benzodiazepines, propofol, or opioids), dexmedetomidine can reduce the need for other sedatives, potentially decreasing time to extubation, reducing delirium incidence, and improving outcomes in ICU patients.
02
Targets
ADRA1A (α1A)ADRA2B (α2B)ADRA2C (α2C)ADRA2A (α2A)
Beyond the preview
Go deeper on standard-of-care + dexmedetomidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on standard-of-care + dexmedetomidine.